Place · Level 3
Ashwagandha · Withania somnifera
印度阿育吠陀 3000 年 · 适应原概念代表 · 皮质醇 RCT 证据 B 级 · 提取物形式差异巨大
Last updated
Story path
Chapter 1
3000 yr Ayurveda
3000 yr Ayurveda
The name Ashwagandha comes from Sanskrit, combining 'horse smell' and 'strength of a horse'.
Foundational facts:
Latin name Withania somnifera, a Solanaceae shrubThe main medicinal part is the root; leaves and berries have different traditional uses and safety profiles3000 years of Ayurvedic use, in India, Nepal, and South AsiaAyurveda classifies it as a rasayana (rejuvenator / adaptogen), traditionally used to improve vitality, sexual function, memory, and longevity
On the concept of adaptogen, introduced by Soviet pharmacologist Lazarev in 1947 and systematized by Brekhman + Dardymov in 1969, with three defining features:
1. Non-toxic at normal doses
2. Non-specific — effective against multiple stressors
3. 'Normalizing' action — returns the body to homeostasis, whether starting from too high or too low
Classic adaptogens typically listed: ashwagandha, rhodiola, ginseng, cordyceps, holy basil, schisandra. The word has no formal FDA/EMA recognition and lives mostly in marketing and integrative medicine, but some of these plants do have RCT evidence — ashwagandha is among them.
Main active compounds
Withanolides: a class of steroidal lactones, ashwagandha's main pharmacologically active substance. Most-studied are withaferin A, withanolide A, withanone. Chemical structure resembles glucocorticoids, so partial effects may go through GR (glucocorticoid receptor) modulation; also acts on GABA / dopamine / serotonin systemsWithanosides: glycosylated withanolidesAlkaloids: trace amounts, used as a sedative in ancient India
Root vs leaf
Traditional use and most RCTs use root, because root has high withanolide content and few alkaloid impurities. Leaf extracts have higher withaferin A but also more cytotoxicity; some commercial products mix leaf and root, possibly explaining some adverse event reports. KSM-66, Sensoril and other proprietary extracts are standardized — see the next scene.
Foundational facts:
Latin name Withania somnifera, a Solanaceae shrubThe main medicinal part is the root; leaves and berries have different traditional uses and safety profiles3000 years of Ayurvedic use, in India, Nepal, and South AsiaAyurveda classifies it as a rasayana (rejuvenator / adaptogen), traditionally used to improve vitality, sexual function, memory, and longevity
On the concept of adaptogen, introduced by Soviet pharmacologist Lazarev in 1947 and systematized by Brekhman + Dardymov in 1969, with three defining features:
1. Non-toxic at normal doses
2. Non-specific — effective against multiple stressors
3. 'Normalizing' action — returns the body to homeostasis, whether starting from too high or too low
Classic adaptogens typically listed: ashwagandha, rhodiola, ginseng, cordyceps, holy basil, schisandra. The word has no formal FDA/EMA recognition and lives mostly in marketing and integrative medicine, but some of these plants do have RCT evidence — ashwagandha is among them.
Main active compounds
Withanolides: a class of steroidal lactones, ashwagandha's main pharmacologically active substance. Most-studied are withaferin A, withanolide A, withanone. Chemical structure resembles glucocorticoids, so partial effects may go through GR (glucocorticoid receptor) modulation; also acts on GABA / dopamine / serotonin systemsWithanosides: glycosylated withanolidesAlkaloids: trace amounts, used as a sedative in ancient India
Root vs leaf
Traditional use and most RCTs use root, because root has high withanolide content and few alkaloid impurities. Leaf extracts have higher withaferin A but also more cytotoxicity; some commercial products mix leaf and root, possibly explaining some adverse event reports. KSM-66, Sensoril and other proprietary extracts are standardized — see the next scene.
withanolide 凭什么插得进去
南非醉茄的主要活性物叫 withanolides, 可以理解成一类甾体内酯 (steroidal lactones)。被研究最多的三个是 withaferin A、withanolide A、withanone。这里有一个关键的形状问题: withanolide 的骨架和糖皮质激素长得很像, 而皮质醇本身就是一种糖皮质激素。
细胞要听懂皮质醇, 靠的是一个叫 GR (糖皮质激素受体) 的接收器: 皮质醇飘过来, 停在 GR 上, GR 带着它进细胞核, 打开一批基因。下丘脑和脑垂体上也装着这套接收器, 它们用它来数血里的皮质醇够不够——够了就少发上游信号。这就是那条链自带的刹车。
于是一个长得像皮质醇、但推力没那么足的分子, 如果能停在刹车这一侧的接收器上, 上游读到的就是够了, 于是少发一点。这是降皮质醇这个说法在分子层面唯一说得通的路径——请注意它目前仍是假说, 不是在人身上直接看到的过程。
除了 GR 这一条, withanolides 还被报告作用在 GABA (让神经元安静下来的信号) 以及多巴胺、血清素系统上, 这是它同时被拿来卖助眠的原因。
其它成分
Withanosides: 挂了糖的 withanolideAlkaloids (生物碱): 含微量, 老印度做镇静用
根 vs 叶: 一个会影响安全的差别
传统使用和大多数临床试验用的都是根, 因为根的 withanolide 含量高, 而生物碱之类杂质少。叶提取物的 withaferin A 含量更高——听起来更强, 但 withaferin A 也是这一家里细胞毒性最强的那个。部分商业产品把叶根混合, 这可能解释了一些副作用案例, 也是后面肝毒那一幕要回来接的一环。KSM-66、Sensoril 等专利提取物有标准化, 见后面讲提取物的那一页。
适应原这个词指什么
南非醉茄常被归到适应原 (adaptogen) 这一类。这个词不是植物学分类, 也不是药理学分类, 而是一个苏联时期造出来的功能性标签: 药理学家 Lazarev 1947 提出, Brekhman + Dardymov 1969 给出系统化定义, 三条:正常剂量下无毒对多种压力源都管用, 不挑压力的种类有归一化作用: 把身体往稳态拉回来, 过高的压下去、过低的提上来
前两条还能验, 第三条是这个概念最松的一环。把偏离的往回拉在生理上确实有对应物, 就是上一页那条链上的负反馈刹车; 但一个宣称高了降、低了升的说法, 在实验里几乎没法被证伪——数值往哪边动都能算它说对了。所以判断一个适应原声称有没有分量, 靠的不是这个标签, 而是它背后有没有指定了方向、人群和终点的临床试验。
经典适应原名单一般还会列 rhodiola (红景天)、ginseng (人参)、cordyceps (虫草)、holy basil (圣罗勒)、schisandra (五味子)。这个词没有 FDA / EMA 正式承认, 多在营销和整合医学里用, 但其中部分植物确实有 RCT (随机对照试验) 证据, ashwagandha 算证据最多的一个。
这株植物本身
几个先垫底的事实:学名 Withania somnifera, 茄科 (Solanaceae) 灌木主要药用部位是根; 叶、浆果用法和安全性不一样3000 年阿育吠陀使用历史, 主要在印度、尼泊尔和南亚名字来自梵语, 由马气味和给人马一样的力气两个意象拼成
这个名字值得多看一眼: 它描述的不是成分, 是期望。三千年里它被当作补元气的药材使用, 而今天货架上天然抗压这四个字, 讲的其实是同一个期望。期望本身不是证据——后面几幕要做的, 就是把期望和真正量到的东西分开摆。
Why this one is most-studied
Ashwagandha has the most RCT data of any adaptogen, due to several stacked reasons:1. Indian government research support: the AYUSH ministry (Ayurveda, Yoga, Unani, Siddha, Homeopathy) funds modernization of traditional medicines, and CSIR (Council of Scientific & Industrial Research) runs multiple ashwagandha research centers; many RCTs are run in Indian clinical hospitals (Sri Sri, KARE, etc.).
2. Perfectly fits the chronic-stress Western era theme: modern life is widely high in cortisol / inflammation / poor sleep / anxiety, and market demand for 'natural + cortisol-regulating' products is large — ashwagandha slots straight into that market.
3. Commercial drivers: KSM-66 (Ixoreal Biomed) is an Indian-developed standardized extract that has funded multiple RCTs; Sensoril (Natreon) is another standardized extract. Patented extract + RCTs = academic data + commercial moat.
4. Signals in multiple clinical domains: stress / anxiety (core), sleep, male fertility / T level (limited), muscle strength / exercise performance, cognition / memory, subclinical thyroid — not a single indication, broad marketing room.
5. Rising Western mainstream acceptance: after 2020 it spread fast through social-media wellness content and podcasts, moving from a niche herb to a routine shelf category. Note how this differs from the first four points — those explain why the research exists, this one only explains why you keep seeing it. Selling well has never been evidence.
But these reasons make it popular, not necessarily effective for you. Real effectiveness depends on RCT quality, dose, extract form, and your specific indication. The next scenes break each of these down.
Chapter 2
HPA modulation · cortisol hypothesis
HPA modulation · cortisol hypothesis
Ashwagandha's main hypothesized mechanism is lowering cortisol and modulating the hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. axis, but the actual biochemistry spans several layers.
① Direct HPA modulation
Withanolides may inhibit CRH / ACTH release, reducing the magnitude of acute stress-induced cortisol spikes. Multiple RCTs measuring blood or salivary cortisol show 14–32% reduction after 8–12 weeks of use:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64 chronically stressed adults, KSM-66 600 mg/day × 60 days, serum cortisol ↓27.9% (vs placebo ↓7.9%) — note: the original trial measured morning *serum*, not salivaryLopresti 2019 (*Medicine*): N=60 stressed adults, 240 mg/day × 60 days, morning cortisol ↓
② GABAergic action
Withanolides partially bind GABA-A receptors, producing a mild benzodiazepine-like sedation. This may be the mechanistic basis for anxiety and sleep improvement, parallel to cortisol reduction.
③ Neurotransmitter modulation
Some animal studies show ashwagandha may upregulate serotonin and dopamine; some RCTs report improvements in depression / anxiety scores.
④ Antioxidant and anti-inflammatory
Withanolides show anti-inflammatory activity in vitro and in animals (nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. inhibition, COX-2 inhibition); some RCTs observe mild drops in C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'., interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation., and other inflammation markers.
⑤ Thyroid modulation
Sharma 2018 (*J Altern Complement Med*): N=50 subclinical hypothyroid, 600 mg/day × 8 weeks → T3 + T4 ↑, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. ↓. This is also why hyperthyroid patients are theoretically contraindicated — it may worsen hyperthyroidism; Hashimoto and subclinical hypothyroid may benefit, but evidence is still preliminary.
Mechanism summary — two boundaries
Evidence-backed: cortisol RCT replicated multiple times (~15–25% drop), subjective stress scores dropHypothesis stage: neurotransmitter, anti-inflammatory, thyroid, sexual function — early evidence, awaiting replicationNo evidence at all: marketing claims like 'anti-aging / skin whitening / direct fat loss'
'Cortisol drop = stress reduction' needs careful interpretation
Lowering cortisol per se doesn't equal health improvement — cortisol is a normal stress response, and too low is also bad (Addison's disease). The key is rhythm restoration (morning high, evening low); ashwagandha probably works more through this path than simple absolute reduction.
Using ashwagandha to replace addressing the root causes of stress (work, sleep, relationships, finances) treats a chemical agent as a cure-all — a common marketing trap.
① Direct HPA modulation
Withanolides may inhibit CRH / ACTH release, reducing the magnitude of acute stress-induced cortisol spikes. Multiple RCTs measuring blood or salivary cortisol show 14–32% reduction after 8–12 weeks of use:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64 chronically stressed adults, KSM-66 600 mg/day × 60 days, serum cortisol ↓27.9% (vs placebo ↓7.9%) — note: the original trial measured morning *serum*, not salivaryLopresti 2019 (*Medicine*): N=60 stressed adults, 240 mg/day × 60 days, morning cortisol ↓
② GABAergic action
Withanolides partially bind GABA-A receptors, producing a mild benzodiazepine-like sedation. This may be the mechanistic basis for anxiety and sleep improvement, parallel to cortisol reduction.
③ Neurotransmitter modulation
Some animal studies show ashwagandha may upregulate serotonin and dopamine; some RCTs report improvements in depression / anxiety scores.
④ Antioxidant and anti-inflammatory
Withanolides show anti-inflammatory activity in vitro and in animals (nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. inhibition, COX-2 inhibition); some RCTs observe mild drops in C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'., interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation., and other inflammation markers.
⑤ Thyroid modulation
Sharma 2018 (*J Altern Complement Med*): N=50 subclinical hypothyroid, 600 mg/day × 8 weeks → T3 + T4 ↑, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. ↓. This is also why hyperthyroid patients are theoretically contraindicated — it may worsen hyperthyroidism; Hashimoto and subclinical hypothyroid may benefit, but evidence is still preliminary.
Mechanism summary — two boundaries
Evidence-backed: cortisol RCT replicated multiple times (~15–25% drop), subjective stress scores dropHypothesis stage: neurotransmitter, anti-inflammatory, thyroid, sexual function — early evidence, awaiting replicationNo evidence at all: marketing claims like 'anti-aging / skin whitening / direct fat loss'
'Cortisol drop = stress reduction' needs careful interpretation
Lowering cortisol per se doesn't equal health improvement — cortisol is a normal stress response, and too low is also bad (Addison's disease). The key is rhythm restoration (morning high, evening low); ashwagandha probably works more through this path than simple absolute reduction.
Using ashwagandha to replace addressing the root causes of stress (work, sleep, relationships, finances) treats a chemical agent as a cure-all — a common marketing trap.
HPA 轴 · 动的是哪一节
hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. 轴 (下丘脑—脑垂体—肾上腺轴) 是那条链的正式名字, 南非醉茄的主要假设机制就落在这里。withanolides 可能抑制 CRH / ACTH 释放, 降低急性应激下皮质醇上升的幅度。多个 RCT 测血或唾液皮质醇, 服 ashwagandha 8-12 周后下降 14-32%:
Chandrasekhar 2012 (Indian J Psychol Med): N=64 慢性应激成人, KSM-66 600 mg/天 × 60 天, 血清皮质醇 ↓ 27.9% (vs 安慰剂 ↓ 7.9%) —— 注意是清晨血清, 不是唾液Lopresti 2019 (Medicine): N=60 应激成人, 240 mg/天 × 60 天, 晨起皮质醇 ↓
清晨血清这四个字为什么要专门标出来
皮质醇一天里本来就是过山车: 醒来后半小时冲到最高, 然后一路往下, 后半夜最低。所以皮质醇降了多少这句话, 离开采样时刻就没有意义——同一个人早上八点和下午三点抽血, 差出来的幅度可以远大于任何补剂造成的差别。而血清测的是总量 (含被结合蛋白抓住的那部分), 唾液测的只是游离的那一小部分, 两者不能直接换算。看到一个百分比, 先问它测的是哪个时刻、哪种样本。
这条链上还差一环
抑制 CRH / ACTH 释放说的是结果, 不是过程。上一幕那条路径 (withanolide 骨架像糖皮质激素, 可能停在负反馈那一端的接收器上) 是目前最讲得通的解释, 但它停在假说层面: 人体试验测到的是血里皮质醇少了, 而链条中间CRH 少发了这一步, 在人身上并没有被直接量过。这是机制清楚和结果可重复之间的差别, 值得你自己分清。
GABA 支线 · 为什么犯困
除了压皮质醇, withanolides 还有一条完全独立的路: 部分结合 GABA-A 受体。GABA (γ-氨基丁酸) 是大脑里最主要的踩刹车信号。它的接收器 GABA-A 不是普通开关, 而是一个氯离子通道: GABA 停上去, 通道打开, 带负电的氯离子涌进神经元, 让细胞内部的电位更负一点。电位更负, 这个神经元就更难被点着。一整片脑区的神经元都难被点着一点, 外在就是: 绷着的那股劲松开、思绪不再打转、更容易睡着。
苯二氮卓类安眠药 (BZD) 走的正是这个通道, 所以文献里常把 withanolides 的作用描述成类苯二氮卓的温和镇静。这条路一次解释了三件本来看着无关的事:
为什么它对焦虑和入睡的改善, 往往比对皮质醇数值的改善更容易被本人感觉到为什么白天发困是它最常见的副作用之一——那不是意外, 那是同一个作用出现在你不想要的时段为什么它和安眠药、镇静剂叠加是危险的: 同一个通道被两样东西一起推, 落点不是简单相加
这条支线与降皮质醇是平行的两条路径, 不是同一件事的两种说法。所以一个人吃了以后更容易睡、皮质醇却没怎么动, 完全说得通。
神经递质 · 抗炎 · 甲状腺
除了 hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. 轴和 GABA 这两条主线, 还有三条被反复提到、但成熟度低得多的路径。③ 神经递质调节
部分动物研究显示 ashwagandha 可能上调血清素和多巴胺, 临床上一些 RCT 看到抑郁、焦虑评分改善。动物研究这四个字要当真: 在啮齿类脑组织里测到递质浓度变化, 和一个人主观感觉好一点之间, 隔着剂量换算、血脑屏障通过率, 以及评分改善里那一大块安慰剂效应。
④ 抗氧化和抗炎
withanolides 在体外和动物里显示出抗炎活性 (nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. 抑制、COX-2 抑制), 部分 RCT 在 C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.、interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. 等炎症标志物上观察到轻度下降。
这两个名字值得拆开看。NF-κB 是细胞里的一个开关蛋白: 炎症信号一到, 它被放开, 跑进细胞核, 把一批炎症基因打开。COX-2 是随后被造出来的一个酶, 负责把花生四烯酸加工成前列腺素, 也就是让局部发红、发热、发痛的那批分子。所以抑制 NF-κB 和 COX-2的意思是在上游少开一点炎症程序, 不是把炎症消灭掉。
⑤ 甲状腺调节
Sharma 2018 (J Altern Complement Med): N=50 亚临床甲减, 600 mg/天 × 8 周, T3 + T4 ↑, thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. ↓。这也是为什么甲亢患者理论上禁用——可能加重亢进; 桥本和亚临床甲减则可能辅助, 但临床证据还只是初步。
这条链的方向值得说清楚: TSH (促甲状腺激素) 是脑垂体发给甲状腺的多做一点的指令, 而甲状腺激素 (T3 / T4) 多了会回头把 TSH 压下去。所以T3 T4 上升 + TSH 下降是一个内部自洽的组合, 说明推力来自甲状腺那一端, 不是脑垂体。甲状腺激素本身是把全身代谢速率往上调的信号: 心跳更快、产热更多、消耗更多。对一个已经甲亢的人 (本来就心慌、怕热、掉体重), 再往同一个方向推, 是叠加而不是纠正——禁用两个字就是这么来的。
机制的边界在哪
机制总结的两个边界真有循证的: 皮质醇 RCT 多次复制 (约 15-25% 下降), 主观应激评分下降假说阶段: 神经递质、抗炎、甲状腺、性功能, 早期证据待复制完全没证据的: 抗衰老、美白、减脂 这类营销说法
皮质醇下降 = 应激减少 要小心解读
降皮质醇本身不等于健康改善——皮质醇是正常的应激反应, 太低也不好 (Addison 病)。关键是节律恢复 (晨高夜低), ashwagandha 可能更多通过这条路起作用, 而不是单纯绝对下降。
为什么节律比数值更值得盯
早上那一波皮质醇不是麻烦, 是功能: 它把肝里存的糖放出来、把血压托起来、把你从睡眠推进清醒。夜里它降下去, 才轮到修复和免疫细胞干活。长期压力把这条曲线压平之后, 人的体感是很典型的一对: 早上起不来, 晚上睡不着。不是精力总量变少了, 是精力发放的时刻错位了。所以一张只写着皮质醇偏高或皮质醇偏低的化验单, 信息量往往小于你一天里几点最有劲这个问题的答案。
如果用 ashwagandha 来替代解决应激根源 (工作、睡眠、关系、经济压力), 就是把化学制剂当万能药, 这是常见的营销陷阱。
Cortisol + stress more nuanced
The cortisol-stress relationship is more nuanced than popular understanding. A few easily-missed points:1. 'High cortisol = stress' is an oversimplification
In healthy people, short-term cortisol rises during stress are adaptive and a good thing. Chronic stress disrupts cortisol rhythm (flattened or inverted), not necessarily raising the average. A meaningful fraction of patients with depression, stress-related fatigue, and chronic fatigue syndrome actually have LOW cortisol and blunted responses.
2. The logic of cortisol-lowering treatment
Truly stressed people: cortisol lowering may restorePeople with already-normal cortisol: lowering it may be pointless or harmful
This explains why ashwagandha shows large individual variation — clear effect in 'stressed groups', vague effect in healthy controls.
3. RCT design limits
Most ashwagandha RCTs enroll people with high stress scores, not ordinary healthy people. Extrapolating to healthy populations needs caution — energetic people without obvious anxiety are unlikely to benefit, and may blunt their stress response.
4. The science of stress management
The core of recovery science is 'rhythm + appropriate stimulus', not 'always low stress'. HRV (heart rate variability) is a better stress indicator than absolute cortisol. Real stress interventions include:
Sleep 7–9 h: the strongest intervention, far exceeding any supplementRegular exercise: acute cortisol ↑, long-term ↓Mindfulness / meditation: RCT-supported for cortisol reductionSocial connection and nature exposureLimit caffeine and screen blue light
5. Ashwagandha's reasonable role
An adjunct, added on top of basic interventions — not a replacement4–8 week trial, watching HRV / sleep / subjective stress score for changeNo response → stop, don't faith-based long-term useSevere anxiety / depression / PTSD: see a professional, not an ashwagandha trial
Chemical adjuncts are vastly inferior to lifestyle redesign — a common conclusion across nearly all nutritional medicine topics, especially in the adaptogen category.
rosmond-2005-psychoneuroendocrinology
Chapter 3
RCT evidence · stress / sleep / muscle
RCT evidence · stress / sleep / muscle
Ashwagandha's clinical RCT evidence stratified by strength.
B-tier (moderate evidence, multiple RCTs but small samples, data mostly from India)
① Chronic stress + anxiety:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64, KSM-66 300 mg × 2/day × 60 days, PSS stress score ↓44%, serum cortisol ↓27.9% (vs placebo ↓7.9%)Lopresti 2019 (*Medicine*, Australia): N=60, 240 mg/day × 60 days, HADS anxiety score ↓Salve 2019 (*Cureus*, India): N=60, KSM-66 250–600 mg/day × 8 wk, anxiety + sleep improvedPratte 2014 review: 5 RCTs show consistent improvement, but samples small, data mostly from India, many KSM-66 company-funded
② Sleep:
Langade 2019 (*Cureus*): N=60 insomnia patients (40 treatment / 20 placebo), 300 mg × 2/day × 10 wk, sleep efficiency 75.6% → 83.5% (placebo 75.1% → 79.7%), sleep-onset latency ↓Salve 2019 also observed improvementMechanism likely GABA + sedation + cortisol rhythm
③ Male T + fertility:
Lopresti 2019 (*Am J Men's Health*): N=57 enrolled / 43 completed, Shoden extract delivering 21 mg withanolide glycosides per day, crossover with 8 weeks per arm (16 weeks total), salivary T ↑14.7%, DHEA-S ↑18%, no between-group difference in cortisol (salivary is a weaker proxy than serum)Ambiye 2013 (*Evid Based Complement Altern Med*): N=46 infertile men, KSM-66 675 mg × 90 days, sperm concentration ↑167%, semen volume ↑53%, motility ↑57% — striking numbers but need large-sample replicationClinical meaning: signal for fertility adjunct, not a replacement for proper reproductive medicine
④ Muscle strength + exercise:
Wankhede 2015 (*J Int Soc Sports Nutr*): N=57 male strength trainees, KSM-66 600 mg × 8 wk, bench press (Δ +46 vs +26 kg) + leg extension (Δ +14.5 vs +9.8 kg) + muscle cross-sectional area ↑Ziegenfuss 2018 (*Nutrients*): N=18 elite athletes, similar resultsEffect size larger than typical supplements; mechanism may be T ↑, cortisol ↓, improved recovery
C-tier (early or single studies)
Subclinical thyroid: Sharma 2018, single studyCognition / memory: a few small studies (Choudhary 2017 etc.)Depression: as antidepressant adjunct (Chengappa 2013 bipolar), earlyOCD: Jahanbakhsh 2016, small study
Claims without evidence (these don't survive scrutiny): longevity / anti-aging, skin whitening, direct fat loss, immune activation.
Several RCT data limitations
Most samples <100, conducted in IndiaMany studies funded by KSM-66 company (Ixoreal Biomed) — doesn't negate results but raises publication bias riskLack of long-term data beyond 6 monthsWestern-population RCTs still scarceNo specific indication approved by FDA or EMA — it's a dietary supplement, not a drug
B-tier (moderate evidence, multiple RCTs but small samples, data mostly from India)
① Chronic stress + anxiety:
Chandrasekhar 2012 (*Indian J Psychol Med*): N=64, KSM-66 300 mg × 2/day × 60 days, PSS stress score ↓44%, serum cortisol ↓27.9% (vs placebo ↓7.9%)Lopresti 2019 (*Medicine*, Australia): N=60, 240 mg/day × 60 days, HADS anxiety score ↓Salve 2019 (*Cureus*, India): N=60, KSM-66 250–600 mg/day × 8 wk, anxiety + sleep improvedPratte 2014 review: 5 RCTs show consistent improvement, but samples small, data mostly from India, many KSM-66 company-funded
② Sleep:
Langade 2019 (*Cureus*): N=60 insomnia patients (40 treatment / 20 placebo), 300 mg × 2/day × 10 wk, sleep efficiency 75.6% → 83.5% (placebo 75.1% → 79.7%), sleep-onset latency ↓Salve 2019 also observed improvementMechanism likely GABA + sedation + cortisol rhythm
③ Male T + fertility:
Lopresti 2019 (*Am J Men's Health*): N=57 enrolled / 43 completed, Shoden extract delivering 21 mg withanolide glycosides per day, crossover with 8 weeks per arm (16 weeks total), salivary T ↑14.7%, DHEA-S ↑18%, no between-group difference in cortisol (salivary is a weaker proxy than serum)Ambiye 2013 (*Evid Based Complement Altern Med*): N=46 infertile men, KSM-66 675 mg × 90 days, sperm concentration ↑167%, semen volume ↑53%, motility ↑57% — striking numbers but need large-sample replicationClinical meaning: signal for fertility adjunct, not a replacement for proper reproductive medicine
④ Muscle strength + exercise:
Wankhede 2015 (*J Int Soc Sports Nutr*): N=57 male strength trainees, KSM-66 600 mg × 8 wk, bench press (Δ +46 vs +26 kg) + leg extension (Δ +14.5 vs +9.8 kg) + muscle cross-sectional area ↑Ziegenfuss 2018 (*Nutrients*): N=18 elite athletes, similar resultsEffect size larger than typical supplements; mechanism may be T ↑, cortisol ↓, improved recovery
C-tier (early or single studies)
Subclinical thyroid: Sharma 2018, single studyCognition / memory: a few small studies (Choudhary 2017 etc.)Depression: as antidepressant adjunct (Chengappa 2013 bipolar), earlyOCD: Jahanbakhsh 2016, small study
Claims without evidence (these don't survive scrutiny): longevity / anti-aging, skin whitening, direct fat loss, immune activation.
Several RCT data limitations
Most samples <100, conducted in IndiaMany studies funded by KSM-66 company (Ixoreal Biomed) — doesn't negate results but raises publication bias riskLack of long-term data beyond 6 monthsWestern-population RCTs still scarceNo specific indication approved by FDA or EMA — it's a dietary supplement, not a drug
B 级证据的原始研究
B 级 (中等证据, 多 RCT 但样本小, 数据多来自印度)慢性应激 + 焦虑是它证据最集中的地方: 多项 RCT 一致看到应激和焦虑评分下降、血清皮质醇下降 (Chandrasekhar 2012 那项降了 27.9%), Pratte 2014 综述汇总 5 个 RCT 结论一致, 但都样本小、多来自印度、不少由 KSM-66 厂家资助。
睡眠上, 失眠者连服 10 周后睡眠效率从 75.6% 升到 83.5%、入睡更快 (Langade 2019, N=60); 另一项 8 周研究在健康成人里也看到改善 (Salve 2019)。机制大概和 GABA 镇静加皮质醇节律有关。
男性睾酮 + 生殖力方向, 信号存在但要谨慎: 唾液睾酮小幅上升 14.7% (Lopresti 2019 Am J Men's Health, 交叉设计每臂 8 周, 唾液是比血清更弱的指标); Ambiye 2013 在不孕男性里报告精子浓度、精液量、活力大幅改善, 数字惊人但需要大样本复制。当辅助有信号, 不替代正规生殖医学。
唾液睾酮为什么要打折看
唾液里能测到的只有游离的那一小部分睾酮, 也就是没被结合蛋白抓住、真正能进细胞的那些。它随采样时刻、口腔里有没有出血、唾液流速一起漂; 血清测的是总量, 稳定得多。所以同一个人身上的唾液睾酮上升, 换成血清未必看得到同样幅度。看到激素类的百分比, 先看它测的是哪种样本。
肌肉力量 + 运动方向效应比一般补剂明显: 力量训练者补 8 周, 卧推、腿部力量和肌肉横截面积都涨得比安慰剂多 (Wankhede 2015、Ziegenfuss 2018), 机制可能是睾酮升、皮质醇降、恢复变好。
为什么压低皮质醇会变成肌肉长得多
皮质醇在肌肉里是往拆那一边推的信号: 它促进肌肉蛋白被分解成氨基酸、送去肝里造糖, 同时压着合成那一侧。肌肉每天都在同时造和拆, 你看到的增长只是两者的差额。所以训练之后如果拆的那一侧被压低一点, 哪怕造的那一侧没变, 差额也会更正一些——这就是降皮质醇能跟围度和力量扯上关系的通路。它顺带解释了为什么这个效应在本来就压力大、睡不好的人身上更容易看到: 差额本来就被压着的人, 松一点就看得出来。
C 级 · 零证据 · 共同软肋
C 级 (早期或单一研究): 甲状腺亚临床 (Sharma 2018)、认知记忆 (Choudhary 2017 等)、抑郁辅助 (Chengappa 2013 双相)、OCD (Jahanbakhsh 2016), 都还是单一或小研究。没有证据的宣传 (这些经不起数据检验): 长寿、抗衰、美白、皮肤、直接减脂、激活免疫。
RCT 数据的几个局限
大多数样本 < 100, 且在印度完成多数研究由 KSM-66 公司 (Ixoreal Biomed) 资助, 不否定结果, 但增加 publication bias 风险缺乏 6 个月以上的长期数据西方人群 RCT 仍少没有任何具体适应症被 FDA 或 EMA 批准, 它是膳食补充, 不是药
厂家资助到底怎么变成偏差的
它不是改数据那么粗暴, 通常也确实没人改。它是这样发生的: 一项试验做出来是阴性的, 于是没人有动力把它写完、投出去、催着被接收——阴性结果本来就更难发表, 而资助方更没有理由推它。若干年后, 文献库里躺着的就只剩那些做出了阳性结果的试验。这时候有人去写一篇综述, 会很诚实地写下结论高度一致。一致是真的, 但那是筛过之后的一致。
它对你的实际含义
一批小型阳性试验的方向一致, 比不上一项大型独立试验的幅度可靠这类文献里的效应量通常被高估, 真实值往往更小但被高估不等于是假的: 这不构成拒绝的理由, 只构成把期望调低的理由真正能压掉这类偏差的, 是预注册方案 + 独立资助 + 样本量足够的复制研究——南非醉茄这一块目前还很缺
Extract forms differ greatly
Ashwagandha isn't one thing — the commercial market splits into at least 4 categories.① Whole root powder — traditional form
Traditional dose 5–10 g/day, taken with warm milk + honey, withanolide content 0.2–0.5%. Pros: complete food matrix, low cost. Cons: hard to standardize, rarely used in modern RCTs.
② KSM-66 (Ixoreal Biomed) — the most widely RCT-studied standardized extract
Withanolide content ≥5% (standardized)Root-only extraction, no leaf, water-based not ethanolMost modern RCTs use thisTypical dose 300 mg × 2/day or 600 mg/dayMany brands use KSM-66 raw material (Nutritional Frontiers / NOW / Sports Research, etc.)
③ Sensoril (Natreon) — another standardized extract
Withanolide ≥10% (higher concentration)Contains leaf + root, safety debatedTypical dose 125–250 mg/day (relatively low)Some RCTs use it
④ Self-standardized / generic extracts — most cheap brands
Labels say 'contains X% withanolides' but actual content varies (ConsumerLab has repeatedly found discrepancies). Products without third-party certification are risky and may contain impurities or heavy metals.
KSM-66 vs Sensoril selection:
Stress + anxiety: most RCTs use KSM-66 600 mg/daySleep: KSM-66 300 mg or Sensoril 250 mg both have dataMale T + muscle: KSM-66 600 mg/daySubclinical thyroid: early data uses KSM-66
Dose ceiling and safety
Highest RCT dose 1000 mg/day; 300–600 mg is usually enough. In the adaptogen concept, small dose long-term is usually better than large dose short-term; don't exceed 12 weeks of uninterrupted use, because long-term data is lacking — a 'drug holiday' is the conservative approach.
4-week trial decision flow:
1. Baseline measurement: stress score (PSS-10), sleep diary, subjective vitality
2. Take KSM-66 600 mg/day × 4 weeks
3. Retest: ≥20% improvement → continue 4 weeks; no change → stop
4. Don't exceed 12 weeks continuous use
5. Watch for side effects: GI upset, drowsiness, any bodily changes
Chapter 4
Side effects + contraindications
Side effects + contraindications
Ashwagandha is NOT a 'natural food with no side effects' — FDA-unregulated doesn't equal risk-free.
Common (≥1%) side effects: GI upset (nausea, diarrhea) ~5–10% (RCT data); drowsiness (consistent with GABA action, usually solvable by dose adjustment); mild headache; fishy or aftertaste.
Rare but important
① Hepatotoxicity (DILI, drug-induced liver injury):
Iceland 2018 + Australia + US 2019–2023 multiple case reports: ashwagandha users developing acute liver injury, with transaminase spikes and bilirubin ↑Most reversible after stopping, but liver transplant cases have been reported**Björnsson 2020 *Liver International***: 5 cases attributed to ashwagandhaMechanism unclear, possibly individual susceptibility, impurities, or stacked drug interactionsRisk factors: pre-existing liver disease, polypharmacy, high doseRecommendation: avoid in those with liver disease history; monitoring ALT / AST during use is reasonable
② Thyroid function effects:
Ashwagandha may raise T3 + T4 (basis for subclinical hypothyroidism studies)Hyperthyroid patients: theoretically contraindicated, may worsenHashimoto / on levothyroxine: monitor dose, may need to reduce medicationHealthy thyroid: usually no effect, but sensitive individuals are exceptions
③ Pregnancy + lactation:
Traditional Ayurveda also used it during pregnancy, but the preparations differModern concerns: withanolides' steroidal structure could theoretically affect hormones and the uterusAnimal studies: high doses induce abortionRecommendation: avoid in pregnancy — not worth taking unknown risks for stress relief
④ Autoimmune disease:
Ashwagandha may modulate immunity, theoretically worsening some autoimmune diseases (lupus, MS, RA, Hashimoto). Data are mixed; real risk is unknown. Patients with diagnosed autoimmune disease should discuss with a doctor before deciding.
⑤ Drug interactions:
Sedatives (BZD, sleep aids, opioids): synergistic sedation, potentially dangerousAntidiabetics: ashwagandha may lower blood sugar; combined with medications may cause hypoglycemiaAntihypertensives: similarThyroid medications: see aboveImmunosuppressants: theoretical antagonismStop 2 weeks pre-surgery (anesthesia synergy + bleeding)
Absolute contraindications:
Pregnancy, trying to conceive (female)Hyperthyroidism (Graves' disease, etc.)Taking thyroid medications without monitoringPrior liver disease or currently on hepatotoxic drugs2 weeks pre-surgeryChildren (<18, no safety data)
Relative contraindications (use with caution after discussion): autoimmune disease (lupus, MS, type 1 diabetes, RA, Hashimoto); polypharmacy; diagnosed depression or anxiety + on medication (discuss with psychiatrist).
'Natural = safe' is a big mistake here — ashwagandha is a compound with genuine pharmacological activity. Use should involve a doctor or pharmacist before and during, not be driven by random purchases on Instagram.
Common (≥1%) side effects: GI upset (nausea, diarrhea) ~5–10% (RCT data); drowsiness (consistent with GABA action, usually solvable by dose adjustment); mild headache; fishy or aftertaste.
Rare but important
① Hepatotoxicity (DILI, drug-induced liver injury):
Iceland 2018 + Australia + US 2019–2023 multiple case reports: ashwagandha users developing acute liver injury, with transaminase spikes and bilirubin ↑Most reversible after stopping, but liver transplant cases have been reported**Björnsson 2020 *Liver International***: 5 cases attributed to ashwagandhaMechanism unclear, possibly individual susceptibility, impurities, or stacked drug interactionsRisk factors: pre-existing liver disease, polypharmacy, high doseRecommendation: avoid in those with liver disease history; monitoring ALT / AST during use is reasonable
② Thyroid function effects:
Ashwagandha may raise T3 + T4 (basis for subclinical hypothyroidism studies)Hyperthyroid patients: theoretically contraindicated, may worsenHashimoto / on levothyroxine: monitor dose, may need to reduce medicationHealthy thyroid: usually no effect, but sensitive individuals are exceptions
③ Pregnancy + lactation:
Traditional Ayurveda also used it during pregnancy, but the preparations differModern concerns: withanolides' steroidal structure could theoretically affect hormones and the uterusAnimal studies: high doses induce abortionRecommendation: avoid in pregnancy — not worth taking unknown risks for stress relief
④ Autoimmune disease:
Ashwagandha may modulate immunity, theoretically worsening some autoimmune diseases (lupus, MS, RA, Hashimoto). Data are mixed; real risk is unknown. Patients with diagnosed autoimmune disease should discuss with a doctor before deciding.
⑤ Drug interactions:
Sedatives (BZD, sleep aids, opioids): synergistic sedation, potentially dangerousAntidiabetics: ashwagandha may lower blood sugar; combined with medications may cause hypoglycemiaAntihypertensives: similarThyroid medications: see aboveImmunosuppressants: theoretical antagonismStop 2 weeks pre-surgery (anesthesia synergy + bleeding)
Absolute contraindications:
Pregnancy, trying to conceive (female)Hyperthyroidism (Graves' disease, etc.)Taking thyroid medications without monitoringPrior liver disease or currently on hepatotoxic drugs2 weeks pre-surgeryChildren (<18, no safety data)
Relative contraindications (use with caution after discussion): autoimmune disease (lupus, MS, type 1 diabetes, RA, Hashimoto); polypharmacy; diagnosed depression or anxiety + on medication (discuss with psychiatrist).
'Natural = safe' is a big mistake here — ashwagandha is a compound with genuine pharmacological activity. Use should involve a doctor or pharmacist before and during, not be driven by random purchases on Instagram.
副作用与肝毒红旗
常见 (≥ 1%) 副作用: 胃肠不适 (恶心、腹泻) 约 5-10% (RCT 数据)、嗜睡或困倦 (与 GABA 作用一致, 通常调整剂量可缓解)、轻度头痛、腥味或后味。罕见但重要 · 肝毒性 (DILI, drug-induced liver injury, 药物性肝损伤)
冰岛 2018 + 澳大利亚 + 美国 2019-2023 多个病例报告: ashwagandha 使用者出现急性肝损伤, 转氨酶飙升, 胆红素 ↑多数停药后可逆, 但有需要肝移植的个案Björnsson 2020 Liver International: 5 例肝损归因 ashwagandha机制不明, 可能是个体敏感、杂质或与其它药物相互作用叠加风险因素: 已有肝病、服多种药物、大剂量建议: 已有肝病史不要用; 使用期间监测 ALT / AST 是合理预防
转氨酶飙升、胆红素升高, 身体里发生的是什么
转氨酶 (ALT / AST) 本来待在肝细胞里面干活。血里能测到一点点, 是正常的细胞更新在漏。血里的数值突然翻好几倍, 意思很直接: 大量肝细胞的膜破了, 里面的东西倒进了血。所以转氨酶不是肝功能好不好的指标, 是肝细胞正不正在被撕开的指标。
胆红素走的是另一条路。它是红细胞退役时血红素留下的残渣, 由肝加工后经胆管排进肠道。这条排泄通路被堵住或者加工不动时, 胆红素积在血里: 于是皮肤和眼白发黄, 而本该染在大便里的色素改从尿里走, 尿色变深像浓茶。这就是为什么发黄 + 茶色尿这一对是最值得认的外在信号——它们对应的是排泄通路出了问题, 而不只是有点累。
南非醉茄相关的肝损报告以胆汁淤积型居多, 也就是更偏向后面这条排泄通路那一侧。
甲状腺 · 妊娠 · 自身免疫
② 甲状腺功能影响ashwagandha 可能升 T3 + T4 (亚临床甲减研究的基础)甲亢患者: 理论禁用, 可能加重桥本、服 levothyroxine: 需要监测剂量, 可能需要减药健康甲状腺: 一般无影响, 但敏感个体例外
为什么在吃优甲乐的人身上这条特别要紧
levothyroxine (优甲乐) 是外源补进去的 T4, 它的剂量是照着你自己的甲状腺还能产多少反推出来的, 医生靠复查 thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. 一点点把它调到刚好。如果这时候有一株植物又从另一侧把 T3 / T4 往上推, 两股力叠在一起, 结果就不是补足而是过头: 体感是心悸、手抖、睡不着、莫名掉体重。麻烦在于这些症状很容易被当成压力大, 而你吃它本来就是因为压力大。所以要加, 就得让开药的医生知道, 并且让复查的 TSH 说话。
③ 妊娠 + 哺乳
传统阿育吠陀也用于妊娠, 但剂型不同现代担忧: withanolides 的甾体结构, 理论上可能影响激素和子宫动物研究: 高剂量诱导流产建议妊娠期避免, 不值得为了应激改善承担未知风险
④ 自身免疫病
ashwagandha 可能调节免疫, 理论上可能加重某些自身免疫病 (狼疮、MS、RA、桥本)。数据混杂, 真正风险未知。已诊断自身免疫病的患者建议与医生讨论后再决定。
值得把方向摆出来: 自身免疫病的本质是免疫系统把自己的组织认成了入侵者, 治疗方向通常是往下压; 而增强免疫力这个卖点讲的是往上推。两个方向相反。所以在这一类病里, 一个连作用方向都还没量清楚的东西, 不该由你自己在货架前决定。
相互作用与禁忌清单
⑤ 药物相互作用镇静药 (BZD、安眠药、阿片): 协同增强镇静, 可能危险降糖药: ashwagandha 可能降血糖, 与药物叠加可能低血糖降压药: 类似甲状腺药: 见上免疫抑制剂: 理论上拮抗手术前 2 周停服 (麻醉协同 + 出血)
这一列里第一条最值得展开: 镇静药和南非醉茄推的是同一个氯离子通道。同一个通道被两样东西一起推, 落点不是把两份镇静相加那么线性, 可能比你预期的深不少——白天的有点困换成夜里的呼吸变浅, 就完全是另一件事了。
绝对禁忌:
怀孕、备孕 (女)甲状腺功能亢进 (Graves 病等)服用甲状腺药物且未监测既往肝病或正在服肝毒药物手术前 2 周儿童 (< 18 岁, 无安全数据)
相对禁忌 (讨论后慎用): 自身免疫病 (狼疮、MS、1 型糖尿病、类风湿、桥本)、多种慢病用药者、抑郁或焦虑确诊 + 服药者 (与精神科医生讨论)。
为什么手术前必须停
麻醉本身就是把中枢神经压下去的一整套药, 其中好几样也走 GABA 那条路。你带着一个自己也在推同一个通道的东西进手术室, 而麻醉师并不知道——他手里的剂量是按没有这个东西算出来的。所以停药不是保险起见, 是让给药的人手里那笔账是对的。同理, 告诉每一位医生和牙医你在吃什么, 是最便宜的一步。
DILI case timeline
The ashwagandha hepatotoxicity reporting timeline is enough to shatter the 'natural = safe' illusion.Björnsson 2020 (Liver International): 5 cases of acute liver injury attributed to ashwagandha — 3 from Iceland and 2 from the US DILIN network. Latency was 2–12 weeks, not 'only after a couple of months': some cases appeared in week two. Presentation was jaundice, pruritus, lethargy and abdominal discomfort with raised transaminases, in a cholestatic or mixed pattern. None of the 5 progressed to hepatic failure; liver tests normalized within 1–5 months in 4 patients, and 1 was lost to follow-up.
2023 report (Philips 2023, India):
An Indian series of 23 ashwagandha-related liver-injury cases, including 3 deaths — all of them patients with pre-existing chronic liver disease who progressed to acute-on-chronic liver failureCumulative global reports continue to riseMostly cholestatic type (jaundice + ALP / GGT ↑)Most recover after stopping; separately, one case has been reported that required emergency liver transplantation (the patient survived)Mechanism hypotheses: individual CYP / UGT polymorphisms; impurities or heavy metal contamination in some sources; leaf-containing extracts (high withaferin A) possibly more toxic than pure rootThis is an idiosyncratic reaction with no clear dose-response threshold, hard to predict
Comparison with other 'natural' DILI: green tea extract (high EGCG) is a major hepatotoxic herb; He Shou Wu (TCM herb) has multiple reports; black cohosh (menopause) supplement has many cases; green coffee bean; Hydroxycut (weight loss); large mixed-protein supplement blends.
US DILIN (Drug-Induced Liver Injury Network) data show herbs + dietary supplements account for ~20% of acute DILI and rising, mainly because of loose regulation, low user self-reporting (not telling doctors), and underestimation of real associations.
Practical recommendations:
1. During ashwagandha use, monitor subjective symptoms: jaundice, upper abdominal pain, tea-colored urine, extreme fatigue
2. Ideal practice: test ALT / AST / ALP / bilirubin before starting, at 4 weeks, and at 12 weeks — especially with multiple supplements
3. Any concern, stop immediately and see a doctor
4. Tell every physician and dentist you take ashwagandha, to avoid drug interactions and anesthesia risk
Conclusion: ashwagandha is NOT 'safe and harmless' — it's 'relatively safe for most people under reasonable use'; but rare-yet-real hepatotoxicity makes it UNSUITABLE for 'insurance-style daily use', and only justified under a specific indication + monitoring + time-limited framework.
Chapter 5
vs other adaptogens
vs other adaptogens
Putting ashwagandha alongside other common adaptogens for comparison.
Rhodiola rosea (Siberian alpine plant)
Actives: salidroside + rosavinTraditional use: Russia and Nordic alpine regions, anti-fatigue + altitude toleranceCharacter: activating type (energizing / anti-fatigue / cognition improvement) — opposite of ashwagandha's sedating typeRCT evidence: short-term anti-fatigue and cognition (Olsson 2009 etc.), B-tier moderate evidenceDose: 200–600 mg standardized extract (3% rosavin / 1% salidroside)Timing: take in the morning to start the day; don't take in the evening — can cause insomnia
Panax ginseng (Asian) + Panax quinquefolius (American)
Actives: ginsenosides (Rb1, Rg1, etc., over 30 forms)Traditional use: East Asia and North America for over 2000 yearsCharacter: mild activating, similar to rhodiolaRCT evidence: cognition (Park 2014), American ginseng for postprandial glucose in diabetes (Vuksan 2000+), anti-fatigue in cancer / chemo-related fatigue (Barton 2013), limited erectile function evidence for red ginseng in menVariety differences (TCM): Korean red (warming) / Chinese white (neutral) / American (cooling)Dose: 200–400 mg standardized extract
Holy basil / Tulsi (Ocimum sanctum): a classic Indian Ayurvedic adaptogen, sedative + stress-modulating like ashwagandha, but with less data, mostly used as tea or extract.
Cordyceps: fungus; traditional *C. sinensis* forms from a moth larva infection; modern products use cultured *C. militaris*. Marketing focuses on energy / adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. / exercise performance; RCT evidence is weak-to-moderate, possibly small improvements in high-intensity exercise performance.
Schisandra (five-flavor berry, East Asian): five flavors (sour, sweet, bitter, pungent, salty); anti-fatigue and liver protection data exists in animals, few human RCTs.
Eleuthero (Siberian 'ginseng', not real ginseng): Latin *Eleutherococcus senticosus*, used historically by Soviet athletes and cosmonauts, anti-fatigue data exists but is variable quality.
Adaptogen selection decisions:
Stress / anxiety / sleep → ashwagandha (KSM-66)Fatigue / poor focus / morning low energy → rhodiola or ginsengExercise recovery → ashwagandha (muscle strength), some add rhodiola for enduranceHigh-altitude travel → rhodiolaChemo / chronic fatigue → ginseng family, discuss with MDDiabetes adjunct → American ginseng (moderate evidence)
But all of these are adjuncts, not core: the real core is sleep, exercise, diet, stress management, and social connection; adaptogens and other supplements are just adjuncts.
If you want to stack multiple adaptogens, be careful: they hit the same pathways (hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol., neurotransmitters, antioxidants) and stacking may amplify side effects. Trying one at a time over 4–8 weeks is more scientific than dropping a whole stack at once.
Rhodiola rosea (Siberian alpine plant)
Actives: salidroside + rosavinTraditional use: Russia and Nordic alpine regions, anti-fatigue + altitude toleranceCharacter: activating type (energizing / anti-fatigue / cognition improvement) — opposite of ashwagandha's sedating typeRCT evidence: short-term anti-fatigue and cognition (Olsson 2009 etc.), B-tier moderate evidenceDose: 200–600 mg standardized extract (3% rosavin / 1% salidroside)Timing: take in the morning to start the day; don't take in the evening — can cause insomnia
Panax ginseng (Asian) + Panax quinquefolius (American)
Actives: ginsenosides (Rb1, Rg1, etc., over 30 forms)Traditional use: East Asia and North America for over 2000 yearsCharacter: mild activating, similar to rhodiolaRCT evidence: cognition (Park 2014), American ginseng for postprandial glucose in diabetes (Vuksan 2000+), anti-fatigue in cancer / chemo-related fatigue (Barton 2013), limited erectile function evidence for red ginseng in menVariety differences (TCM): Korean red (warming) / Chinese white (neutral) / American (cooling)Dose: 200–400 mg standardized extract
Holy basil / Tulsi (Ocimum sanctum): a classic Indian Ayurvedic adaptogen, sedative + stress-modulating like ashwagandha, but with less data, mostly used as tea or extract.
Cordyceps: fungus; traditional *C. sinensis* forms from a moth larva infection; modern products use cultured *C. militaris*. Marketing focuses on energy / adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. / exercise performance; RCT evidence is weak-to-moderate, possibly small improvements in high-intensity exercise performance.
Schisandra (five-flavor berry, East Asian): five flavors (sour, sweet, bitter, pungent, salty); anti-fatigue and liver protection data exists in animals, few human RCTs.
Eleuthero (Siberian 'ginseng', not real ginseng): Latin *Eleutherococcus senticosus*, used historically by Soviet athletes and cosmonauts, anti-fatigue data exists but is variable quality.
Adaptogen selection decisions:
Stress / anxiety / sleep → ashwagandha (KSM-66)Fatigue / poor focus / morning low energy → rhodiola or ginsengExercise recovery → ashwagandha (muscle strength), some add rhodiola for enduranceHigh-altitude travel → rhodiolaChemo / chronic fatigue → ginseng family, discuss with MDDiabetes adjunct → American ginseng (moderate evidence)
But all of these are adjuncts, not core: the real core is sleep, exercise, diet, stress management, and social connection; adaptogens and other supplements are just adjuncts.
If you want to stack multiple adaptogens, be careful: they hit the same pathways (hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol., neurotransmitters, antioxidants) and stacking may amplify side effects. Trying one at a time over 4–8 weeks is more scientific than dropping a whole stack at once.
红景天与人参
Rhodiola rosea (红景天、西伯利亚高山植物)活性物: salidroside + rosavin传统使用: 俄罗斯和北欧高山地区, 抗疲劳 + 高海拔耐受特点: 激活型 (提神、抗疲劳、改善认知), 与 ashwagandha 的镇静型相反RCT 证据: 短期抗疲劳和认知 (Olsson 2009 等), B 级中等证据剂量: 200-600 mg 标准化提取物 (3% rosavin / 1% salidroside)使用时机: 早晨, 帮助开启一天; 不要晚上服, 容易失眠
Panax ginseng (人参) + Panax quinquefolius (花旗参)
活性物: 人参皂苷 (ginsenosides), 已鉴定出的有上百种, 常被研究的只有 Rb1 / Rg1 等几种传统: 东亚和北美 2000 年以上特点: 温和激活, 类似红景天RCT 证据: 认知方面部分 RCT 阳性 (Park 2014 等); 花旗参在糖尿病餐后血糖控制有数据 (Vuksan 2000+ 等); 抗疲劳方面慢性疲劳和化疗后疲劳改善 (Barton 2013); 男性勃起功能有红参的有限证据种类差别 (中医分类): 韩国红参 (温) / 中国白参 (中) / 美国花旗参 (凉)剂量: 200-400 mg 标准化提取物
标准化提取物上那个百分数在说什么
红景天那一行括号里的两个百分数, 说的是: 这瓶粉末里每一百份, 有三份是 rosavin、一份是 salidroside。植物长在哪、什么时候采、用什么溶剂提, 都会让这个比例漂; 所谓标准化, 就是厂家把它拉到一个固定值, 好让吃了多少毫克这句话跟吃进去多少活性物对得上。
这也是为什么单看毫克数没有意义: 同样重量的两瓶粉末, 一瓶标了活性物比例、另一瓶没标, 你实际吃进去的可能差好几倍。买这一类东西时, 标签上有没有这个百分数, 比品牌名有用得多。
虫草 · 五味子 · 刺五加
Holy basil / Tulsi (圣罗勒, Ocimum sanctum): 印度阿育吠陀经典适应原, 与 ashwagandha 类似的镇静 + 应激调节, 但数据较少, 多以茶或提取物形式使用。Cordyceps (虫草): 真菌, 传统 C. sinensis 是蝙蝠蛾幼虫感染形成, 现代多用培养的 C. militaris。营销集中在能量 / adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. / 运动表现, RCT 证据弱到中等, 高强度运动表现可能小幅改善。
Schisandra (五味子): 东亚, 五种味道 (酸、甜、苦、辣、咸), 抗疲劳 + 肝保护方面有动物数据, 人体 RCT 很少。
Eleuthero (西伯利亚人参, 不是真人参): 学名 *Eleutherococcus senticosus*, 苏联运动员、宇航员历史使用, 抗疲劳数据存在但质量参差。
这几种和前两种的差别, 在证据落在哪一层
差别不在有没有作用, 而在谁被量过。动物数据和人体试验之间隔着三道坎: 剂量换算 (啮齿类代谢快得多)、给药途径 (灌胃 vs 你吞一颗胶囊)、以及终点 (肝里某个酶的活性 vs 你明天有没有精神)。所以看到动物研究显示保护肝脏这种句子, 正确的读法不是它护肝, 而是这是一条值得拿到人身上去验的线索, 而这一步还没做。
虫草那条里的 ATP 也一样。ATP 是细胞里通用的能量货币, 但跟 ATP 有关并不等于你会更有精神——身体里几乎每件事都跟 ATP 有关。这个词在营销里的作用是让人联想到能量, 而不是指出一个具体的作用点。
怎么选 · 为什么别叠加
适应原选择决策:应激、焦虑、睡眠 → ashwagandha (KSM-66)疲劳、注意力差、上午没劲 → rhodiola 或人参运动恢复 → ashwagandha (肌肉力量), 部分人加 rhodiola 改善耐力高海拔旅行 → rhodiola化疗、慢性疲劳 → 人参类, 与医生讨论糖尿病辅助 → 花旗参 (中等证据)
但这些都是辅助, 不是核心: 真正的核心是睡眠、运动、饮食、应激管理和社交连接; 适应原和其它补剂只是辅助。
如果你想叠加多个适应原, 需要慎重: 它们影响相同的通路 (hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol.、神经递质、抗氧化), 叠加可能放大副作用。一次试一种 + 4-8 周观察, 比同时上一套全家桶更科学。
一次一种, 不只是为了安全
同时上三样, 你会撞上一个没法解的局面: 万一有效, 你不知道是哪一样在起作用, 于是只能三样一直吃下去; 万一出了副作用, 你也不知道该停哪一样, 只能三样一起停, 然后从头再来。一次一种换来的是下一轮你知道该怎么做, 这比省下的那几周值钱得多。
而且这几种植物指向的方向本来就不一样: 一个往下压、一个往上提, 同时吃就是一脚油门一脚刹车。身体最后落在哪, 不由你决定。
Boundaries of 'adaptogen' concept
Is 'adaptogen' actually a useful clinical concept? The academic community is still debating.Supporters:
Mechanistically, the hypothalamic–pituitary–adrenal axis: The body's stress-response chain (hypothalamus → pituitary → adrenal) that releases cortisol. axis really can be modulated by various plants — not pure fantasyClinical data: some plants (ashwagandha, rhodiola, ginseng) do show RCT evidence on stress / fatigue endpointsEU EMA grants 'Traditional Herbal Registration' (THR) status to certain plants — doesn't require modern RCTs, just decades of documented traditional use
Critics:
The concept is too broad — 'modulates the body back to homeostasis' fits almost any effective drug, lacking specificityHard to measure — stress resistance lacks objective biomarkers (beyond cortisol and HRV)Publication bias — adaptogen RCTs tend to be small and selectively publish positive resultsAlternative medicine packaging — the word 'adaptogen' is used for many plants with no RCT data at all, blurring real vs fake
FDA / EMA stance: 'adaptogen' is not an FDA-recognized disease or sign; sold as a dietary supplement under the DSHEA 1994 framework. The structure-function claim loophole allows 'supports stress response' but not 'treats anxiety'. EMA THR registers some plants but only acknowledges traditional use — not modern medical validation.
Neutral practical stance:
Acknowledge that some plants (ashwagandha, rhodiola, ginseng) have B-tier RCT data and are worth considering as adjunctsDon't accept 'adaptogens can cure or prevent specific diseases' — that's marketing overreachReal stress management = sleep + exercise + diet + psychology + social connection + therapy or medication if needed — the combined effect of these vastly exceeds all adaptogens combined
3 principles of use:
1. Specific goal: not 'I hope to be healthier' but 'my stress score is high, I want to try 4–8 weeks and see if anything changes'
2. Baseline measurement + tracking: without testing you won't know, and testing nothing after a trial is the same
3. Time-limited use: 4–12 week cycles with breaks — no dependence, no long-term faith
Final metaphor: adaptogens are keys that sometimes open a door — but you DON'T NEED this key to enter the room of 'real health change', because that door is ALWAYS OPEN, inside 'adequate sleep + regular exercise + diverse diet + social connection'. Keys are adjuncts — don't let marketing make you think the door is locked without one.
References · 9
- Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3), 255–262. 10.4103/0253-7176.106022
- Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine, 98(37), e17186. 10.1097/MD.0000000000017186
- Salve, J., et al. (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus, 11(12), e6466. 10.7759/cureus.6466
- Lopresti, A. L., Drummond, P. D., & Smith, S. J. (2019). A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. American Journal of Men's Health, 13(2), 1557988319835985. 10.1177/1557988319835985
- Ambiye, V. R., Langade, D., Dongre, S., Aptikar, P., Kulkarni, M., & Dongre, A. (2013). Clinical evaluation of the spermatogenic activity of the root extract of ashwagandha (Withania somnifera) in oligospermic males: a pilot study. Evidence-Based Complementary and Alternative Medicine, 2013, 571420. 10.1155/2013/571420
- Wankhede, S., Langade, D., Joshi, K., Sinha, S. R., & Bhattacharyya, S. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. Journal of the International Society of Sports Nutrition, 12, 43. 10.1186/s12970-015-0104-9
- Sharma, A. K., Basu, I., & Singh, S. (2018). Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: A double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine, 24(3), 243-248. N=50; 600 mg/day × 8 weeks lowered TSH and raised T3/T4 in subclinical hypothyroidism. 10.1089/acm.2017.0183
- Björnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., et al. (2020). Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver International, 40(4), 825-829. Five cases of cholestatic/mixed liver injury after 2-12 weeks of ashwagandha use; all self-limited. pubmed.ncbi.nlm.nih.gov/31991029
- Philips, C. A., Valsan, A., et al. (2023). Ashwagandha-induced liver injury — A case series from India and literature review. Hepatology Communications, 7(10), e0270. 23 herb-induced liver injury cases; cholestatic predominant; patients with pre-existing chronic liver disease had severe (fatal) outcomes. 10.1097/HC9.0000000000000270